Nuclear Medicine Theranostics: Perspective from Pakistan

다국어 초록 (Multilingual Abstract)

Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.

참고문헌 (Reference)

1 Hofman MS, "[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer(LuPSMA trial) : a single-centre, single-arm, phase 2 study" 19 : 825-833, 2018

2 Riaz S, "Triage of limited versus extensive disease on F18 FDG PET/CT scan in small cell lung cancer Asia Ocean" 5 : 109-113, 2017

3 Younis N, "Theranostics–neuroendocrine tumours" 4 (4): 1-, 2018

4 Bodei L, "The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy(PRRNT)in neuroendocrine tumours" 40 : 800-816, 2013

5 Gavan SP, "The economic case for precision medicine" 3 : 1-9, 2018

6 Zaman MU, "Significantly low effective dose from 18FDG PET/CT scans using dose reducing strategies: "lesser is better"" 17 : 3465-3468, 2016

7 Ajit S, "Rhenium 188 : the poor Man’s yttrium" 16 : 1-2, 2017

8 Sawin CT, "Radioiodine and the treatment of hyperthyroidism : the early history" 7 : 163-176, 1997

9 Strosberg J, "Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors" 376 : 125-135, 2017

10 Atutornu J, "Personalized medicine and medical imaging : opportunities and challenges for contemporary health care" 49 : 352-359, 2018

11 Kunikowska J, "Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors : the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management" 42 : 905-911, 2017

12 Mittra ES, "Neuroendocrine tumor therapy : 177Lu-DOTATATE" 211 : 278-285, 2018

13 Sharp SE, "MIBG in neuroblastoma diagnostic imaging and therapy" 36 : 258-278, 2016

14 Memon AS, "Isolation period of 131I administered patients at NIMRA Jamshoro Pakistan" 2 : 2-5, 2017

15 Ahmadzahehfar H, "Iodine-131-lipiodol therapy in hepatic tumours" 55 : 246-252, 2011

16 Riaz S, "Impact and prognostic value of 18F FDG PET-CT scan in the evaluation of residual head and neck cancer-single centre experience from Pakistan" 6 : 81-83, 2017

17 Zaman MU, "High-dose I131 therapy on outpatient basis : imperative and no more a desire" 2 : 92-97, 2012

18 Strosberg J, "Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial" 36 : 2578-2584, 2018

19 Handkiewicz-Junak D, "EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides" 45 : 846-859, 2018

20 Riaz S, "Diagnostic accuracy of 18F-FDG PET-CT in the evaluation of carcinoma of unknown primary" 25 : 1-10, 2016

21 Virgolini I, "Current status of theranostics in prostate cancer" 45 : 471-495, 2018

22 Ajit S, "An overview of nuclear medicine and PET CT in India" 1 (1): 2017

23 Hassan A, "18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma : a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement" 44 : 1198-1206, 2017

24 Rizzieri D. Z, "(ibritumomabtiuxetan)after more than a decade of treatment experience, what have we learned" 105 : 5-17, 2016